Cyclacel Pharmaceuticals Inc. entered into a Warrant Exchange Agreement on September 4, 2025, with certain accredited investors, exchanging Series C common stock purchase warrants for 559,395 shares of the company's common stock. The exchange did not involve a cash transaction, and the shares were issued without registration under the Securities Act of 1933, relying on the exemption provided by Section 3(a)(9). The document does not specify the price of the shares.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cyclacel Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-026571), on September 04, 2025, and is solely responsible for the information contained therein.